Diamyd Medical AB

Clinical trials sponsored by Diamyd Medical AB, explained in plain language.

Diamyd Medical AB DMYD-B NASDAQ STOCKHOLM

A Swedish biotech developing a diabetes vaccine (Diamyd) for type 1 diabetes.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1 Terminated 1

New shot aims to keep insulin flowing in type 1 diabetes

Disease control Stopped early

This study tests a drug called Diamyd in people aged 12 to 29 who were recently diagnosed with type 1 diabetes and have a specific genetic type (HLA DR3-DQ2). The goal is to see if Diamyd can help the body keep making its own insulin, which could improve blood sugar control and r…

Phase 3 • Sponsor: Diamyd Medical AB • Aim: Disease control

Last updated Aug 28, 2026 00:00 UTC

Diamyd Medical AB

New shot aims to keep insulin flowing in type 1 diabetes